Table 2 Efficacy Outcomes
Category | Patients Treated With Lenvatinib 24 mg Once Daily (N = 26) | |
|---|---|---|
Investigator Assessment | IIR | |
Objective response rate, n (%) (90% CI) | 3 (11.5) (3.2–27.2) | 3 (11.5) (3.2–27.2) |
Best overall response, n (%) | ||
 Complete response | 0 | 0 |
 Partial response | 3 (11.5) | 3 (11.5) |
 Stable disease | 19 (73.1) | 9 (34.6) |
 Progressive disease | 4 (15.4) | 13 (50.0) |
 Not evaluable | 0 | 0 |
 Unknown | 0 | 1 (3.8) |
Disease control ratea, n (%) (90% CI) | 22 (84.6) (68.2–94.6) | 12 (46.2) (29.2–63.8) |
Clinical benefit rateb, n (%) (90% CI) | 10 (38.5) (22.6–56.4) | 6 (23.1) (10.6–40.5) |
PFS rate at 12 weeks, % (95% CI) | 72.2 (50.4–85.7) | 44.0 (24.5–61.9) |
Median PFS, months (95% CI) | 3.19 (2.79–7.23) | 1.64 (1.41–3.19) |
Median time to progression, months (95% CI) | 4.11 (2.76–7.39) | 1.64 (1.41–2.92) |
Median overall survival, months (95% CI) | 7.35 (4.50–11.27) | |